Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. Academic Article uri icon

Overview

MeSH

  • Administration, Oral
  • Adult
  • Aged
  • Humans
  • Middle Aged

MeSH Major

  • Antineoplastic Agents
  • Ganciclovir
  • Herpesvirus 8, Human
  • Sarcoma, Kaposi

abstract

  • We conducted a clinical trial of oral valganciclovir, a drug with in vitro activity against Kaposi sarcoma (KS)-associated herpesvirus (KSHV), in classic KS. Five human immunodeficiency virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalovirus infection. None of the study subjects showed an objective response; KS progressed in 4 subjects after 1-4 cycles and remained stable in 1 subject after 6 cycles. KS biopsies showed minimal lytic KSHV antigen and gene expression at baseline and no treatment-associated changes. Although valganciclovir was not active against KS in this setting, other appropriately targeted anti-herpesviral strategies may prove to be more effective. © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

publication date

  • April 15, 2011

has subject area

  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents
  • Ganciclovir
  • Herpesvirus 8, Human
  • Humans
  • Middle Aged
  • Sarcoma, Kaposi

Research

keywords

  • Journal Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiq177

PubMed ID

  • 21450998

Additional Document Info

start page

  • 1082

end page

  • 1086

volume

  • 203

number

  • 8